The money for the bulk of our trials is provided by the research partners we work with as we know and being a thirdparty if they don’t think the trial is worth the investment they kill it...
there’s a reason why they continue to fund their Multiple trials with our drug Paxalisib, in multiple conditions and there’s a reason why we continue in discussions with other clinicians on potential new trials.
we have heard about concerns around financing for the last 5 years and yet years later here we are with money in the bank Some 1- million and multiple data readouts on the way for this year alone and 6 trials underway.
im not worried about where the money is coming from I’m worried that if we do a partner deal we don’t do it too early as we want full value with this game changing, better than the standard of care compound we are bringing to peoples lives and the market.
KZA Price at posting:
49.5¢ Sentiment: Buy Disclosure: Held
